文献速递传染病防控与疫情报告免疫规划

尼日尔与尼日利亚疫情应对中五价脑膜炎球菌结合疫苗首次使用的强化被动安全性监测

Enhanced passive safety surveillance during the first use of the meningococcal vaccine A/C/W/Y/X conjugate for outbreak response in Niger and Nigeria.
PubMed 文献 · Vaccine · 2026-03-05

在2024年尼日尔和尼日利亚的脑膜炎疫情应对中,首次大规模使用五价脑膜炎球菌结合疫苗(MMCV),并同步开展强化被动安全性监测。共接种4,881,027人,报告1109例免疫接种后不良事件(AEFI),报告率为22.7/10万接种者,其中11例(0.99%)为严重事件,包括1例死亡。大多数AEFI为轻度且发生于接种当日,未发现新的安全性信号。

要点

  • MMCV在疫情应对中大规模接种后,严重AEFI发生率极低,安全性特征与临床试验一致。
  • 强化被动监测结合数字工具和综合督导,可及时、全面地报告AEFI。
  • 常见AEFI为发热、注射部位反应、肌痛、关节痛和头痛,多发生于接种当日。

核心结论

  • MMCV在尼日尔和尼日利亚疫情应对中的实际使用证实了稳健的安全性,严重不良事件率极低且未发现新安全性信号。

研究设计与样本

  • 在尼日尔(2024年5-7月)和尼日利亚(2024年3-6月)MMCV接种活动中开展强化被动安全性监测,包括系统化AEFI报告、数字工具(尼日利亚MedSafety App®、尼日尔ODK Collect®)、综合督导和系统化数据监测。

主要发现

  • 共接种4,881,027人(尼日尔2,697,934人;尼日利亚2,183,093人),报告1109例AEFI,报告率为22.7/10万接种者。
  • 11例(0.99%)AEFI被分类为严重事件,包括1例死亡。
  • 大多数AEFI为轻度且发生于接种当日,最常见为发热、注射部位反应、肌痛、关节痛和头痛。
  • AEFI报告多数为2-12岁儿童(61.9%),其次为青少年(17.4%)和年轻成人(15.2%)。

关键数值与推荐

  • 使用VigiBase®和Vigilyze®进行不相称性分析以识别潜在安全性信号,未检测到新安全性信号。

临床怎么用

  • 在疫情应对中大规模引入MMCV时,应实施强化被动安全性监测,并利用数字工具和综合督导提高AEFI报告及时性和全面性。
  • 持续投资药物警戒基础设施和医护人员培训对有效疫苗安全性监测至关重要。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The African meningitis belt remains prone to recurrent invasive meningococcal disease (IMD) outbreaks, mainly from serogroups C, W, and X. In 2024, Niger and Nigeria conducted the first large-scale, real-world use of the pentavalent meningococcal conjugate vaccine (MMCV), covering Neisseria meningitidis serogroups A, C, W, Y, and X. This study describes enhanced passive safety surveillance implemented during these campaigns. METHODS: Enhanced passive safety surveillance was conducted during MMCV campaigns in Niger (May-July 2024) and Nigeria (March-June 2024). Surveillance included systematic adverse event reporting, digital tools (MedSafety App® in Nigeria, ODK Collect® in Niger), integrated supervision and systematic data monitoring. Adverse Events Following Immunization (AEFI) were analyzed by demographics, seriousness, and System Organ Class (SOC). Disproportionality analysis was performed using VigiBase® and Vigilyze® to identify potential safety signals. FINDINGS: A total of 4,881,027 individuals were vaccinated (Niger: 2,697,934; Nigeria: 2,183,093). There were 1109 AEFI reports (reporting rate: 22.7 per 100,000 vaccinees), with 11 (0.99%) classified as serious, including one death. Most AEFIs were mild and occurred on the day of vaccination; the most frequent were pyrexia, injection site reactions, myalgia, arthralgia, and headache. The majority of AEFI reports were among children aged 2-12 years (61.9%), followed by adolescents (17.4%) and young adults (15.2%). INTERPRETATION: The introduction of MMCV in Niger and Nigeria confirmed a robust safety profile in real-world outbreak settings, with very low rates of serious adverse events and no new safety signals detected. Enhanced passive surveillance, supported by digital tools and integrated supervision, enabled timely and comprehensive AEFI reporting. The observed safety outcomes were consistent with clinical trial data and previous vaccine introductions, reinforcing the reliability and generalizability of MMCV's safety. Sustained investment in pharmacovigilance infrastructure and ongoing training for healthcare workers remain essential for effective vaccine safety monitoring.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Menang O, Gambo M, Keoulon KC, et al. Enhanced passive safety surveillance during the first use of the meningococcal vaccine A/C/W/Y/X conjugate for outbreak response in Niger and Nigeria. Vaccine. 2026. PMID: 41791242. doi:10.1016/j.vaccine.2026.128390

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。